Aurobindo Pharma stock is performing well. Sales in Europe are improving. New products are launching in the US. The company is also developing weight loss drugs. Future growth will come from more product launches and a recent acquisition. Backward integration projects are also boosting profitability. The company expects strong earnings growth.
Positive Breakout: These 7 stocks cross above their 200 DMAs
In the Nifty500 pack, seven stocks’ closing prices crossed above their 200 DMA (Daily Moving Averages) on April 7, 2026, according to stockedge.com’s technical scan